Studies of short-term prednisolone therapy in children with HBeAg positive chronic type B hepatitis

We have studied the effect of short-term prednisolone therapy in 9 children with HBeAg positive chronic type B hepatitis, aged 6 to 13 years. All children were started on treatment with prednisolone (1.0-1.5mg/kg/day) orally at the level of s-GPT being more than 140IU/L (140-673IU/L). Prednisolone w...

Full description

Saved in:
Bibliographic Details
Published inKanzo Vol. 26; no. 7; pp. 830 - 837
Main Authors SHIMIZU, Masaru, TAKAI, Emiko, YASUDA, Masanori, TANAKA, Hiroshi, ADACHI, Nobuyuki, KOJIMA, Mineo, TSUDA, Fumio, AIHARA, Shinobu, TAKAHASHI, Yoshiyata
Format Journal Article
LanguageJapanese
Published The Japan Society of Hepatology 1985
Subjects
seroconversion
Online AccessGet full text
ISSN0451-4203
1881-3593
DOI10.2957/kanzo.26.830

Cover

More Information
Summary:We have studied the effect of short-term prednisolone therapy in 9 children with HBeAg positive chronic type B hepatitis, aged 6 to 13 years. All children were started on treatment with prednisolone (1.0-1.5mg/kg/day) orally at the level of s-GPT being more than 140IU/L (140-673IU/L). Prednisolone was decreased and discontinued gradually for period of 21 to 36 days. During follow-up study for 13 to 19 months after treatment, HBeAg disappeared from serum in 8 out of 9 children (88.9%). 5 out of 9 children (55.6%) have seroconverted from HBeAg to anti-HBe. Only one cleared HBsAg by RIA. 8 children in whom HBeAg disappeared achieved a complete and protracted remission. All children were free of severe side effects with this therapy.
ISSN:0451-4203
1881-3593
DOI:10.2957/kanzo.26.830